



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/203353/2013

European Medicines Agency decision

P/0112/2013

of 30 April 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human lysosomal acid lipase (EMEA-001331-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0112/2013

of 30 April 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human lysosomal acid lipase recombinant human lysosomal acid lipase (EMA-001331-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Synageva BioPharma Ltd on 31 July 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 March 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human lysosomal acid lipase, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant human lysosomal acid lipase, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Synageva BioPharma Ltd, c/o Kevin Beare & Co., 3-5 Horndean Road, Berkshire, RG12 0XQ Bracknell, United Kingdom.

Done at London, 30 April 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/18805/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-001331-PIP01-12

Scope of the application

Active substance(s):

Recombinant human lysosomal acid lipase

Condition(s):

Treatment of Lysosomal Acid Lipase Deficiency

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

Synageva BioPharma Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Synageva BioPharma Ltd submitted for agreement to the European Medicines Agency on 31 July 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 12 September 2012.

Supplementary information was provided by the applicant on 14 December 2012.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 15 March 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Lysosomal Acid Lipase Deficiency

2.1.1. Indication(s) targeted by the PIP

Treatment of Early Onset Lysosomal Acid Lipase Deficiency/ Wolman disease.

Treatment of Late Onset Lysosomal Acid Lipase Deficiency/ Cholesteryl ester storage disease.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion.

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	3	Measure 1: Rat Developmental Toxicity and Toxicokinetic Intravenous Infusion Study (Seg II) Measure 2: Rabbit Developmental Toxicity and Toxicokinetic Intravenous Infusion Study (Seg II) Measure 3: Intravenous Infusion Pre- and Post-Natal Study in the Rat.
Clinical	3	Measure 4: Open-label, multi-centre, dose escalating, historical controlled trial to evaluate, pharmacokinetics, safety, efficacy, immunogenicity of recombinant human lysosomal acid lipase in children from birth to 2 years of age with Lysosomal Acid Lipase Deficiency. Measure 5: Double-blind, randomised, placebo controlled trial to evaluate, pharmacokinetics, safety, efficacy, immunogenicity of recombinant human lysosomal acid lipase in children from 4 years of age and adults with Late Onset Lysosomal Acid Lipase Deficiency or Cholesteryl ester storage disease (including adults). Measure 6: Open-label, multi-centre, trial to evaluate the safety, tolerability, and immunogenicity of recombinant human lysosomal acid lipase in a broad population of subjects with LAL Deficiency (including adults).

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2016
Deferral for one or more measures contained in the paediatric investigation plan:	Yes